NASDAQ:TCRX TScan Therapeutics Q2 2026 Earnings Report $0.31 -0.02 (-6.48%) Closing price 09/18/2026 04:00 PM EasternExtended Trading$0.32 +0.01 (+3.24%) As of 09/18/2026 07:22 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. ProfileEarnings HistoryForecast TScan Therapeutics EPS ResultsActual EPS-$0.23Consensus EPS -$0.25Beat/MissBeat by +$0.02One Year Ago EPSN/ATScan Therapeutics Revenue ResultsActual Revenue$1.05 millionExpected Revenue$1.88 millionBeat/MissMissed by -$824.00 thousandYoY Revenue GrowthN/ATScan Therapeutics Announcement DetailsQuarterQ2 2026Date8/12/2026TimeBefore Market OpensConference Call DateWednesday, August 12, 2026Conference Call Time7:00AM ETUpcoming EarningsTScan Therapeutics' Q3 2026 earnings is estimated for Wednesday, November 11, 2026, based on past reporting schedules, with a conference call scheduled at 9:30 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) TScan Therapeutics Earnings HeadlinesTScan Therapeutics consensus price target decreased by 55.56% to $2.72September 16, 2026 | msn.comHC Wainwright Issues Optimistic Estimate for TCRX EarningsSeptember 12, 2026 | americanbankingnews.comGold did this exact thing in 1975… [then exploded]In 1975 the Fed raised rates and gold fell 50 percent. Headlines called the gold bull market dead. Instead gold climbed from 100 dollars in 1976 to 850 dollars by 1980, a 750 percent gain in under five years. Today the new Fed chair has floated another rate hike, and investors are reacting the same way they did in 1975. Analyst Garrett Goggin, CFA, CMT, founder of Golden Portfolio, says the setup rhymes with that era.September 20 at 1:00 AM | Golden Portfolio (Ad)TScan Therapeutics (NASDAQ:TCRX) Stock Rating Lowered by HC WainwrightSeptember 10, 2026 | americanbankingnews.comWedbush downgrades TScan Therapeutics (TCRX) to neutral from outperformSeptember 3, 2026 | msn.comTScan Therapeutics Reorganizes To Focus On Solid Tumor Program; To Cut 75% Jobs; Stock Tumbles 11%September 2, 2026 | rttnews.comSee More TScan Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like TScan Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on TScan Therapeutics and other key companies, straight to your email. Email Address About TScan TherapeuticsTScan Therapeutics (NASDAQ:TCRX) is a clinical-stage biotechnology company focused on developing T cell receptor (TCR) engineered T cell therapies for the treatment of cancer. The company’s approach is designed to equip a patient’s T cells with tumor-specific TCRs that can recognize cancer-related targets presented on the surface of tumor cells. TScan’s research and development programs address both solid tumors and hematologic malignancies. Its platform is intended to identify and validate cancer targets and matching TCRs, which may support the development of multiple targeted cell therapies for patients whose tumors express particular antigens. The company’s pipeline includes investigational therapies directed at selected tumor-associated targets, and its programs remain in clinical development. Founded in 2018, TScan Therapeutics is headquartered in Waltham, Massachusetts, and conducts its clinical and research activities primarily in the United States. The company is led by David Southwell, who serves as president and chief executive officer. TScan became a publicly traded company on the Nasdaq exchange in 2021.View TScan Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles J.B. Hunt's Stock Plunges After Market Misprices Profit WarningLennar’s Earnings Miss May Be Sending a Bigger Warning About U.S. HousingThese 3 Stocks Sit at the Center of NVIDIA’s Cybersecurity PushGold Has Gone Sideways, But These 3 Stocks Haven’tLennar's Q3 Miss Hides a Stronger Operating Story Beneath the Housing SlumpAeluma’s Selloff Could Be Setting Up Its Next Big MoveBraze Beat Expectations—Now 2 SaaS Peers Are in Focus Upcoming Earnings Cintas (9/23/2026)Costco Wholesale (9/24/2026)Micron Technology (9/30/2026)NIKE (10/1/2026)Accenture (10/1/2026)PepsiCo (10/8/2026)Delta Air Lines (10/9/2026)America Movil (10/13/2026)BlackRock (10/13/2026)Citigroup (10/13/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
